Life Sciences Research Reagents and Supplies M&A update, 14–28 September 2026
A bi-weekly briefing on the Life Sciences Research Reagents and Supplies sector for September 14–28, 2026, covering public market moves, company news, and precedent M&A activity for operators, acquirers and advisors tracking the space.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Life Sciences Research Reagents and Supplies Sector Outlook — September 2026
Key figures
- Sector median move
- +22.5%
- Bi-weekly, close-to-close
- S&P 500 return
- +0.8%
- Same window
- Quanterix (QTRX) move
- +40.8%
- Bi-weekly, close-to-close
- Precedent transaction multiple
- 24.2x
- Median EV/LTM EBITDA, trailing record
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES
Executive summary
Over September 14–28, 2026, all 9 covered names rose, with a +22.5% median move against +0.8% for the S&P 500. The two largest gainers, Quanterix (+40.8%) and Alpha Teknova (+34.9%), each carried in-window product or leadership news. No new sector transaction was announced, leaving the trailing record of 20 precedent deals at a 24.2x EV/EBITDA median as the reference point. The period reads as execution-led, not deal-led.
Key findings
- All 9 covered names rose, median +22.5%, versus +0.8% for the S&P 500.
- Quanterix (+40.8%) and Alpha Teknova (+34.9%) led on product and leadership news.
- No new transactions priced the space; the trailing record holds at 24.2x EV/EBITDA.
- Standing valuation view stays anchored on EV/Revenue, not this period's price moves.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES
Cover slide introducing the bi-weekly Life Sciences Research Reagents and Supplies industry events and M&A update for September 14–28, 2026.
This update covers the two-week window from September 14 to 28, 2026 across the Life Sciences Research Reagents and Supplies space. We'll walk through what moved, why it most likely moved, what transacted, and what it means for the people running these businesses.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES Execution News Lifts the Whole Set While Deal Flow Waits What moved across Life Sciences Research Reagents and Supplies over the two-week period of September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Company Execution, Not Transactions, Carried the Period
This page shows that all nine covered companies rose over the period, with a +22.5% median move against a +0.8% S&P 500 return, while no new transactions priced the sector.
Every one of the 9 companies we track finished the two-week period higher, with a median move of +22.5% versus +0.8% for the S&P 500 — so this was a broad, sector-wide move, not a handful of outliers. The two largest gainers, Quanterix at +40.8% and Alpha Teknova at +34.9%, each carried their own product or leadership news inside the window. No new sector transaction was announced in the period, so the trailing record of 20 precedent transactions at a 24.2x EV/EBITDA median remains the reference point. For us, that combination says execution, not deal activity, set prices this period.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Company Execution, Not Transactions, Carried the Period The two-week period in one page · 9 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Every Covered Name Finished the Two-Week Period Higher 9 of 9 covered names rose; the median move was +22.5%. The S&P 500 returned +0.8% over the same window. 2 The Two Largest Gainers Both Carried Their Own In-Window News Quanterix Corporation (QTRX) rose +40.8% and Alpha Teknova, Inc. (TKNO) rose +34.9%. Each had a product or leadership announcement inside the window. 3 No New Transaction Priced the Set This Period No material sector transactions were announced during the period. The trailing record of 20 precedent transactions still carries a median of 24.2x EV/EBITDA. 4 A Two-Week Rally Does Not Move the Standing Tiers NeuraCap's standing view reads this set on EV / Revenue, with a 9.1x sector median for CY2027E and a Premium tier median of 16.7x. The period's moves are consistent with that frame rather than a challenge to it. +40.8% Best mover — Quanterix Corporation (QTRX) worst: SEER +6.3% · 9 up / 0 down of 9 covered +22.5% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
Product Capacity and Senior Hires Drove the Period's Biggest Moves
This page ranks the period's biggest public market movers and ties each to the filings or headlines recorded in the window, using a ±33.7% sector-relative materiality bar.
We measure every move close-to-close against a sector median of +22.5% and a materiality bar of ±33.7%, so we can separate genuine outliers from routine drift. Quanterix led at +40.8% and Alpha Teknova followed at +34.9%, and both moves sit above that bar. We attribute each move only to what's actually on record in the filings and headlines from the window — where nothing is recorded, we say so rather than guess. That discipline is what lets us call this an execution-driven rally with confidence.
Everything on this page
PUBLIC MARKET MOVERS Product Capacity and Senior Hires Drove the Period's Biggest Moves Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +22.5% · S&P 500 +0.8% · materiality bar ±33.7% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +22.5% Quanterix Corporation (QTRX) +40.8% Shares moved following two company announcements in the window: the September 14 appointment of Dr. Yuri Fesko as Chief Medical Officer, and the inducement grants reported on September 16. The largest single day was Sep 15 at +8.8%. A NeuraCap read: Discount-tier names can move hard when the market sees hiring aimed at the clinical path. COMPANY-SPECIFIC Alpha Teknova, Inc. (TKNO) +34.9% The move appears to reflect the Fill-Tek dispensing system announced on September 16, which fills single-use bag orders across multiple sizes as a single lot with no added turnaround time. The largest single day was Sep 21 at +7.1%. Core-tier suppliers get paid for custom and bulk manufacturing capacity, not only for catalog SKUs. COMPANY-SPECIFIC
- 04MAJOR NEWS & INDUSTRY CATALYSTS
Companies Spent the Period Adding Capacity, Content and Leadership
This page lists the period's highest-impact company news, spanning product launches, partnerships, capacity additions and senior leadership hires, each linked to its source.
The headline events this period were operating, not financial: a media and feed launch, a biopharma discovery partnership, added custom fill capacity, and senior leadership hires. Each entry links back to the underlying filing or article, and our 'why it matters' read sits alongside the primary source. This is the evidence base behind the share-price moves we just reviewed — so the two pages read together, not separately. It's this operating news, not deal announcements, that is doing the work this period.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period Adding Capacity, Content and Leadership The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · Business Wire Thermo Fisher launches the Gibco CHO-K1 catalog panel of media and feed for biologics work A cGMP-ready basal and feed portfolio aimed at bioproduction adds catalog SKUs where reorders follow the process rather than the instrument. That is the spec-in position the diversified platforms keep building toward. Regulated-grade media is where the largest suppliers are choosing to compete for repeat orders. Sep 21 · NEWS · GlobeNewsWire Seer announces a transition in its Chief Financial Officer role At a platform-stage proteomics name, the finance seat sits closest to the placement-to-pull-through story the market is underwriting. A change there is worth watching for how the recurring mix is framed. Leadership continuity carries weight when the revenue model is still converting instruments into kits. Sep 16 · NEWS · Business Wire Twist Bioscience joins Lilly TuneLab to advance antibody drug discovery A Premium-tier name putting its synthetic DNA capability inside a partner's AI discovery platform is a route to being spec'd into someone else's workflow. Biopharma-weighted demand is the steadier end of the mix. Partnerships with biopharma platforms can build attach rate without new instrument placements. Sep 16 · NEWS · GlobeNewsWire Teknova expands custom manufacturing with the Fill-Tek single-use bag filling system Filling multiple bag sizes and quantities as a single lot with no added turnaround speaks directly to lot-to-lot consistency and lead time in bioproduction supply. Those are the terms on which custom accounts stay. Custom and bulk mix is where Core-tier suppliers separate themselves from commodity consumables. Sep 16 · NEWS · Business Wire Quanterix reports inducement grants made to a recently appointed senior executive The grants sit alongside a run of senior appointments in the same window. The signal is a company building out commercial and clinical leadership rather than trimming it. Where a company hires at the top says where it expects its next revenue to come from. Sep 14 · NEWS · Business Wire Quanterix appoints Dr. Yuri Fesko as Chief Medical Officer Putting a physician executive in a new Chief Medical Officer seat points at the research-use-only to regulated-grade path, which is where durability in biomarker franchises is decided. Clinical leadership hires mark intent to move product toward regulated grade.
- 05M&A & STRATEGIC ACTIVITY
The Reference Set Stands on the Trailing Record This Period
This page shows that no new sector transaction was announced in the period, leaving the trailing record of 20 precedent deals at a 24.2x EV/LTM EBITDA median as the standing reference.
No new transaction priced the sector during September 14–28, so we're standing on the trailing record this period: 20 recorded precedent deals with a median of 24.2x EV/LTM EBITDA. We don't re-present old transactions as news — this page simply confirms the reference point acquirers and targets are working from right now. For acquirers, that means the last confirmed deal evidence is still the best guide to where multiples clear. The gap between a rallying public set and a quiet deal market is itself worth watching into the next period.
Everything on this page
M&A & STRATEGIC ACTIVITY The Reference Set Stands on the Trailing Record This Period September 14–28, 2026 · precedent transactions: 20 recorded deals · median 24.2x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The pricing evidence remains the trailing record of 20 precedent transactions, which carries a median of 24.2x EV/EBITDA. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 20 Recorded precedent transactions the reference set buyers and sellers price against 24.2x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
- 06WHAT IT MEANS
What a Broad, News-Led Rally Means for People Running These Businesses
This page translates the period's broad, news-led rally into implications for owners and operators, acquirers, and advisors.
For owners and operators, operating news set the prices this period — the biggest gainers each had their own product or leadership announcement behind the move. For acquirers, share prices moved but the transaction evidence didn't, so the 20-deal precedent record at 24.2x EV/EBITDA is still the number to anchor on. For advisors, the case to make right now is execution evidence — the launches, partnerships, capacity additions and hires we tracked this period. These are observations drawn from the recorded evidence, not recommendations, and each audience should read them against its own position.
Everything on this page
WHAT IT MEANS What a Broad, News-Led Rally Means for People Running These Businesses The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 9.1x 9 companies in the study 3 valuation tiers Standing thesis: Life Sciences Research Reagents and Supplies Trades as Four Businesses, and the Faster Growers Hold the Top FOR OWNERS & OPERATORS Operating News Set the Prices This Period Companies in the space traded higher across the board, and the two largest gainers each carried their own product or leadership announcement. FOR ACQUIRERS Share Prices Moved; The Transaction Evidence Did Not No new transactions were signed in the window, so the trailing record of 20 precedent transactions and its 24.2x EV/EBITDA median is still the reference point. FOR ADVISORS Lead with Execution Evidence This Period The theme was company execution: a media and feed launch, a biopharma discovery partnership, added custom fill capacity, and senior hires.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
This page documents the sources and methodology behind the update, including how figures are sourced and how driver attributions are made.
Every figure in this update links back to the record it came from — SEC filings, consensus estimates, or market prices through September 28, 2026. Driver attributions use calibrated language because they are our reads of the recorded evidence, not claims of proven cause. We rely on a fixed source order — filings, press releases, then established outlets — and we don't draw on video or social platforms. That discipline is what makes every number and every read in this deck traceable back to something a reader can open.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T212310Z_571_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com
Sources and methodology
This update covers Life Sciences Research Reagents and Supplies over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Life Sciences Research Reagents and Supplies under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: BioLife Solutions, Inc. (BLFS), Illumina, Inc. (ILMN), Nautilus Biotechnolgy, Inc. (NAUT), Quantum-Si incorporated (QSI), Quanterix Corporation (QTRX), Seer, Inc. (SEER), Alpha Teknova, Inc. (TKNO), Thermo Fisher Scientific Inc. (TMO), Twist Bioscience Corporation (TWST). No covered name fell below the floor in this window.
Window and company universe
This update covers Life Sciences Research Reagents and Supplies over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Life Sciences Research Reagents and Supplies under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: BioLife Solutions, Inc. (BLFS), Illumina, Inc. (ILMN), Nautilus Biotechnolgy, Inc. (NAUT), Quantum-Si incorporated (QSI), Quanterix Corporation (QTRX), Seer, Inc. (SEER), Alpha Teknova, Inc. (TKNO), Thermo Fisher Scientific Inc. (TMO), Twist Bioscience Corporation (TWST). No covered name fell below the floor in this window.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 20 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +40.8% (businesswire.com)
- +34.9% (globenewswire.com)
- Thermo Fisher launches the Gibco CHO-K1 catalog panel of media and feed (businesswire.com)
- Seer announces a transition in its Chief Financial Officer role (globenewswire.com)
- Twist Bioscience joins Lilly TuneLab to advance antibody drug discovery (businesswire.com)
- Quanterix reports inducement grants made to a recently appointed senior (businesswire.com)
- businesswire.com (businesswire.com)
- globenewswire.com (globenewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Life Sciences Research Reagents and Supplies Sector Outlook — September 2026
- M&A Update · 29 September 2026Life Sciences Tools and Instruments M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Life Sciences Tools and Instruments Sector Outlook — September 2026
- M&A Update · 29 September 2026Managed Health Care M&A update, 14–28 September 2026
Want this analysis for a company in Life Sciences Research Reagents and Supplies?
Company valuation reports run the same method against a single business — public or private.
